Street View: Lilly remains the front-runner as GLP-1 demand climbs

U.S. drugmaker Eli Lilly LLY.N reported a sharp rise in second-quarter sales of its Zepbound and Mounjaro injections, beating analyst forecasts and further widening the competitive gap with Danish rival Novo Nordisk NOVOb.CO.

Median PT of 34 brokerages covering the stock is $1,300 - LSEG-compiled data.

** Morgan Stanley ("overweight," PT: $1419) says LLY's strong Q2 results and increased 2026 guidance reinforced their positive view of the co's GLP-1 portfolio and the long-term growth potential of the obesity market

** J.P. Morgan ("overweight," PT: $1,400) says LLY remains their top pick, citing potential upside to market expectations over the next few years and upcoming catalysts that could strengthen its lead in the obesity and diabetes drug market

** Morningstar (fair value: $980) says strong demand for recently launched, high-margin drugs across multiple indications supports expectations for double-digit growth through the end of the decade

** RBC Capital Markets ("outperform," PT: $1,500) says it remains optimistic about LLY's prospects, driven by expected gains from Medicare coverage expansion, overseas markets and its drug development pipeline